Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) CFO Colleen Tupper sold 10,445 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total transaction of $313,454.45. Following the completion of the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Colleen Tupper also recently made the following trade(s):
- On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00.
Collegium Pharmaceutical Trading Down 1.8 %
Shares of NASDAQ COLL opened at $29.10 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a market cap of $916.24 million, a PE ratio of 12.54 and a beta of 0.99. The company has a 50-day moving average of $30.85 and a two-hundred day moving average of $33.05. Collegium Pharmaceutical, Inc. has a 1-year low of $27.28 and a 1-year high of $42.29.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Collegium Pharmaceutical
Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in shares of Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after buying an additional 175,892 shares during the last quarter. Penserra Capital Management LLC bought a new stake in Collegium Pharmaceutical in the third quarter valued at approximately $757,000. Barclays PLC increased its stake in Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after purchasing an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC increased its stake in Collegium Pharmaceutical by 10.7% in the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company's stock valued at $695,000 after purchasing an additional 1,731 shares in the last quarter. Finally, FMR LLC increased its stake in Collegium Pharmaceutical by 1,532.2% in the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company's stock valued at $1,459,000 after purchasing an additional 35,439 shares in the last quarter.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the stock. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler dropped their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price for the company in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $43.60.
Check Out Our Latest Stock Report on COLL
About Collegium Pharmaceutical
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
